Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer

BACKGROUND: Both hormonal therapy (HT) and maintenance capecitabine monotherapy (MCT) have been shown to extend time to progression (TTP) in patients with metastatic breast cancer (MBC) after failure of taxanes and anthracycline-containing regimens. However, no clinical trials have directly compared...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Chin J Cancer
Hauptverfasser: Chen, Xue-Lian, Du, Feng, Hong, Ruo-Xi, Wang, Jia-Yu, Luo, Yang, Li, Qing, Fan, Ying, Xu, Bing-He
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2016
Schlagworte:
Original Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4845336/
https://ncbi.nlm.nih.gov/pubmed/27112139
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40880-016-0101-7
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge